학술논문

Evaluating Leukocyte Telomere Length and Myeloid-Derived Suppressor Cells as Biomarkers for Prostate Cancer.
Document Type
Article
Source
Cancers. Apr2024, Vol. 16 Issue 7, p1386. 11p.
Subject
*LEUCOCYTES
*BIOPSY
*GENOMICS
*RESEARCH funding
*LOGISTIC regression analysis
*PROSTATE tumors
*MYELOID-derived suppressor cells
*TUMOR markers
*DNA
*DESCRIPTIVE statistics
*MULTIVARIATE analysis
*PERIPHERAL circulation
*AGING
*TELOMERES
*COMPARATIVE studies
*CONFIDENCE intervals
Language
ISSN
2072-6694
Abstract
Simple Summary: Prostate cancer is the most common cancer in men. The pursuit of novel biomarkers for early detection of prostate cancer poses a contemporary challenge given the age-associated escalation in prostate cancer risk and severity. Our focus was directed towards evaluating leukocyte telomere length (LTL) and myeloid-derived suppressor cells (MDSC) in prostate cancer patients, considering their potential as adjunctive diagnostic markers. In a study of 102 patients who underwent prostate biopsy, those diagnosed with prostate cancer demonstrated significantly shorter LTL and an increased proportion of M-MDSC prior to diagnosis, along with elevated PSA levels and age, in comparison to controls. Furthermore, a significant negative correlation was observed between LTL and MDSC levels. This initial report of those findings could potentially contribute to a deeper understanding of the molecular, biological, and immunological factors involved in cancer development. Background: Leukocyte telomere length (LTL) and myeloid-derived suppressor cells (MDSC) are associated with aging and the development and progression of cancer. However, the exact nature of this relationship remains unclear. Our study aimed to investigate the potential of LTL and MDSC as diagnostic biomarkers for prostate cancer while also seeking to deepen our understanding of the relationship of these potential biomarkers to each other. Methods: Our study involved patients undergoing a prostate biopsy. We analyzed the relative LTL in genomic DNA obtained from peripheral blood leukocytes as well as the percentage of MDSC and their subtypes in peripheral blood mononuclear cells (PBMC). Our evaluation focused on examining the relationship between LTL and MDSC and pathological diagnoses as well as investigating the correlation between LTL and MDSC levels. Results: In our study of 102 participants, 56 were pathologically diagnosed with localized prostate cancer (cancer group), while 46 tested negative (control group). The cancer group exhibited significantly shorter LTL in comparison to the control group (p = 0.024). Additionally, the cancer group showed a tendency towards a higher percentage of monocytic MDSC (M-MDSC), although this difference did not reach statistical significance (p = 0.056). Our multivariate logistic regression analysis revealed that patients with shorter LTL and higher percentages of M-MDSC had a 2.98-fold (95% CI = 1.001–8.869, p = 0.049) and 3.03-fold (95% CI = 1.152–7.977, p = 0.025) increased risk of prostate cancer diagnosis, respectively. There was also a significant negative correlation between LTL and M-MDSC. (r = −0.347, p < 0.001). Conclusions: Our research has established a correlation between LTL and MDSC in patients undergoing biopsy for prostate cancer. Notably, we observed that individuals with localized prostate cancer tend to have shorter LTL and a higher percentage of M-MDSC prior to their diagnosis. These findings suggest that LTL and M-MDSC could potentially serve as adjunctive biomarkers for the early diagnosis of prostate cancer. [ABSTRACT FROM AUTHOR]